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ABSTRACT 
In this work, Ebola epidemic outbreak cases and deaths were modeled 
using compartmental model of epidemic mathematics and kinetics. 
Data were obtained from credible internet sources like Centers for 
Disease Control (CDC) and World Health Organization (WHO) which 
were used to validate our model, and the results show that it was  
almost a perfect model for some countries of West Africa but just good enough for Central 
Africa as the R
2
 shows. The goodness of fit terms of coefficient of correlation (R
2
) of the 
developed model on test data gives excellent validation. For Guinea, R
2
 is 0.9997 for both 
cases and deaths test data. For Liberia, R
2
 is 0.9977 for both cases and deaths test data. For 
Sierra Leone, R
2
 is 0.9997 (for cases) and 0.9995 (for deaths data). For Nigeria, R
2
 is 0.9914 
(for cases data) and 0.9979 (for deaths data). For Central Africa, R
2
 is 0.9343 (for cases data) 
and 0.9304 (for deaths data). The response plot of the cumulative cases and deaths as well as 
the monthly cases and deaths between the three worst-hit countries, namely (Liberia, Guinea. 
Sierra Leone) show very serious interaction since the EVD is spread by bats, gorillas, 
herbivorous animals that live in the bush and thick forest. We should reduce the rate of 
contact with the animals and stop eating them especially their carcasses found in the bushes 
and thickets. These findings can be used in studying future ebola epidemic and pandemic 
outbreaks by World Health Organization (WHO), Pan American Health Organization (Pan-
AHO), Centers for Disease Control (CDC), etc. 
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NOMENCLETURE 
CACC  Central African cumulative cases 
CACD  Central African cumulative deaths 
CACF  Central African cumulative fatality 
LCC  Liberia cumulative cases 
LCD  Liberia cumulative deaths 
LCF  Liberia cumulative fatality 
SCC  Sierra-Leone cumulative cases 
SCD  Sierra-Leone cumulative deaths 
SCF  Sierra-Leone cumulative fatality 
GCC  Guinea cumulative cases 
GCD  Guinea cumulative deaths 
GCF  Guinea cumulative fatality 
NCC  Nigeria cumulative cases 
NCD  Nigeria cumulative deaths 
NCF  Nigeria cumulative fatality 
EVD  Ebola Virus Diseases 
SIS  susceptible Infected susceptible 
EHF  Ebola hemorrhagic fever 
 
1.0   INTRODUCTION 
1.1   BACKGROUND INFORMATION 
Infections with Ebola viruses originating from Africa cause a severe disease in humans, 
Ebola virus disease (EVD). Since the first documented EVD outbreak in Zaïre (now: the 
Democratic Republic of Congo) in 1976, five species of the genus Ebola virus (Filoviridae 
family) have been identified from samples collected from humans and non-human primates 
during outbreaks of the disease: Zaïre Ebola virus (EBOV), Sudan Ebola virus, Reston Ebola 
virus, Taï-Forest Ebola virus and Bundibugyo Ebola virus (Bustillo et al., 2014; CDC, 2014). 
Ebola viruses and Marburg virus, another member of the Filoviridae family, are classified as 
biosafety level 4 pathogens (BSL-4; risk group 4) and require special containment measures 
and barrier protection, in particular for healthcare workers. The map below (Fig 1) presents 
www.wjert.org  
 
15 
Mahesh et al.                                  World Journal of Engineering Research and Technology 
the geographical distribution of Ebola outbreaks from 1976 to 2011 in Africa (CDC 2015). 
The advanced world was not taking the outbreak serious because they thought it’s an African 
problem, an epidemic that span from 1986 to 2012 was not taken serious by the advanced 
world until the disease was carried by the animals in the oldest forest in the world (Congo). It 
did not stop there but began to spread to the advanced countries themselves. The virus is 
transmitted to people from wild animals and spreads in the human population through 
human-to-human transmission. Fruit bats of the Pteropodidae family are considered to be the 
natural host of the Ebola virus. Severely ill patients require intensive supportive care. No 
licensed specific treatment or vaccine is available for use in people or animals. Ebola first 
appeared in 1976 in 2 simultaneous outbreaks, in Nzara, Sudan, and in Yambuku, Democratic 
Republic of Congo. The latter was in a village situated near the Ebola River, from which the 
disease takes its name (WHO, 2014; Chowell et al., 2004). 
 
Genus Ebolavirus is 1 of 3 members of the Filoviridae family (filovirus), along with genus 
Marburgvirus and genus Cuevavirus. Genus Ebolavirus comprises of 5 distinct species. 
1. Bundibugyo ebolavirus (BDBV) 
2. Zaire ebolavirus (EBOV) 
3. Reston ebolavirus (RESTV) 
4. Sudan ebolavirus (SUDV) 
5. Taï Forest ebolavirus (TAFV). 
 
BDBV, EBOV, and SUDV have been associated with large EVD outbreaks in Africa, 
whereas RESTV and TAFV have not. The RESTV species, found in Philippines and the 
People’s Republic of China, can infect humans, but no illness or death in humans from this 
species has been reported to date (WHO, 2014; Chowell et al., 2004).. 
 
1.2   TRANSMISSION 
Ebola is introduced into the human population through close contact with the blood, 
secretions, organs or other bodily fluids of infected animals. In Africa, infection has been 
documented through the handling of infected chimpanzees, gorillas, fruit bats, monkeys, 
forest antelope and porcupines found ill or dead in the rainforest. Ebola then spread in the 
community through human-to-human transmission, with infection resulting from direct 
contact (through broken skin or mucous membranes) with the blood, secretions, organs or 
other bodily fluids of infected people, and indirect contact with environments contaminated 
with such fluids. Burial ceremonies in which mourners have direct contact with the body of 
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the deceased person can also play a role in the transmission of Ebola. Men who have 
recovered from the disease can still transmit the virus through their semen for up to 7 weeks 
after recovery from the illness (Nishira and Chowell, 2014; Althaus et al., 2014). 
 
Health-care workers have frequently been infected while treating patients with suspected or 
confirmed EVD. This has occurred through close contact with patients when infection control 
precautions are not strictly practiced. Among workers in contact with monkeys or pigs 
infected with Reston Ebola virus, several infections have been documented in people who 
were clinically asymptomatic. Thus, RESTV appears less capable of causing disease in 
humans than other Ebola species (Althaus et al., 2014; Funk and Kumar, 2014). More studies 
of RESTV are needed before definitive conclusions can be drawn about the pathogenicity and 
virulence of this virus in humans. 
 
EVD is a severe acute viral illness often characterized by the sudden onset of fever, intense 
weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhoea, 
rash, impaired kidney and liver function, and in some cases, both internal and external 
bleeding. Laboratory findings include low white blood cell and platelet counts and elevated 
liver enzymes (Nishiura and Chowell, 2014). The incubation period, that is, the time interval 
from infection with the virus to onset of symptoms, is 2 to 21 days. 
 
The problem is that these epidemic or rather pandemic outbreak cases and deaths trends has 
not been adequately modeled mathematically to really represent the real live situations. It is 
important to study the outbreak trend so as to mathematically model the process trend and so 
as to help Ebola nations predict the next outbreak, peak cases and deaths. The objective of 
this work is therefore to mathematically model the Ebola outbreak trend profile so as to study 
the characteristics of the peak cases and deaths for Central and West Africa. The scope of this 
work covers the mathematical modeling and prediction of the profile scenario of the disease 
outbreak in Central and West Africa, so that the Ebola countries can use this work findings as 
a guide, and does not include high and advanced mathematical models. 
 
2.0   LITERETURE REVIEW 
Ebola virus disease (EVD; also called Ebola hemorrhagic fever, or EHF), or simply Ebola, is 
a disease of humans and other primates caused by Ebola viruses. Signs and symptoms 
typically start between two days and three weeks after contracting the virus with a fever, sore 
throat, muscle pain, and headaches. Then, vomiting, diarrhea and rash usually follow along 
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with decreased function of the liver and kidneys. At this time some people begin to bleed 
both internally and externally (WHO and Pan-AHO, 2014). The disease has a high risk of 
death, killing between 25 and 90 percent of those infected with an average of about 50 
percent. This is often due to low blood pressure from fluid loss, and typically follows six to 
sixteen days after symptoms appear. (Sunit, 2014). 
 
The virus spreads by direct contact with body fluids, such as blood, of an infected human or 
other animals. This may also occur through contact with an item recently contaminated with 
bodily fluids. Spread of the disease through the air between primates, including humans, has 
not been documented in either laboratory or natural conditions (CDC, 2014). Semen or breast 
milk of a person after recovery from EVD may still carry the virus for several weeks to 
months. Fruit bats are believed to be the normal carrier in nature, able to spread the virus 
without being affected by it. Other diseases such as malaria, cholera, typhoid fever, 
meningitis and other viral hemorrhagic fevers may resemble EVD. Blood samples are tested 
for viral RNA, viral antibodies or for the virus itself to confirm the diagnosis. (CDC, 2014) 
Ebola virus first broke out in Zaire and Sudan in 1976. Mortality rates were put at 88% in 
Zaire and 66% in Sudan, with 500 cases. In one small village in Zaire, 274 out of 300 people 
infected in an outbreak died. This disease resurfaced in 1995 according to the Zairian health 
ministry affecting medical professionals. 170 had died as of May 11th 1995 in response to 
people fleeing Kikwit and possibly spreading the virus. The government of Zaire attempted to 
cordon off the city to keep inhabitants from spreading the disease across the countryside and 
possibly even into the slums of Kinshasa, Zaire's capital. Kikwit was put under quarantine. It 
was unable, at that period, to contain the spread of the virus even with the support of 
international medical experts from Belgium, France, and South Africa. Poor health 
infrastructure, inadequate proactive measures can be attributed to the failure of the 
government during that time to contain the spread (Pourrut, 2005). 
 
In recent times, the Ebola virus was reported first in Guinea in March 2014. Now the virus 
has spread to other West African nations like Liberia, Sierra Leone, Nigeria, and Senegal. 
The major scare of this deadly virus is the number of lives that have already been claimed 
ranging from 42%-66 %.( WHO, 2014; Salaam-Blyther, 2014). As of September 10th 2014, a 
total of 2,281 deaths had been recorded out of 4,614 suspected or confirmed cases. One 
immediate reaction by government authorities was to regulate movement through partial or 
total closure of borders (Morvan et al., 1999). 
www.wjert.org  
 
18 
Mahesh et al.                                  World Journal of Engineering Research and Technology 
2.1   SIGNS AND SYMPTOMS OF EBOLA 
The length of time between exposure to the virus and the development of symptoms 
(incubation period) is between 2 to 21 day. However, recent estimates based on mathematical 
models predict that around 5% of cases may take greater than 21 days to develop. Symptoms 
usually begin with a sudden influenza-like stage characterized by feeling tired, fever, 
weakness, decreased appetite, muscle pain, joint pain, headache, and sore throat. This is often 
followed by vomiting, diarrhea and abdominal pain (FART, 2015; Goeijenbier et al., 2014). 
In about half of the cases, the skin may develop a maculopapular rash, a flat red area covered 
with small bumps, 5 to 7 days after symptoms begin. In some cases, internal and external 
bleeding may occur, typically beginning in five to seven days after the first symptoms, all 
infected people showing some decreased blood clotting and bleeding from mucous 
membranes or from sites of needle punctures as reported in 40–50 percent of cases. This may 
cause vomiting or coughing out blood, or blood in stool. Bleeding into the skin may create 
petechiae, purpura, ecchymoses or hematomas (especially around needle injection sites). 
Heavy bleeding is uncommon; if it occurs, it is usually located within the gastrointestinal 
tract (Hoenen et al., 2012). 
 
Recovery may begin between 7 and 14 days after first symptoms. Death, if it occurs, follows 
typically 6 to 16 days from first symptoms and is often due to low blood pressure from fluid 
loss. In general, bleeding often indicates a worse outcome, and blood loss may result in death. 
People are often in a coma near the end of life and those who survive often have ongoing 
muscle and joint pain, liver inflammation, decreased hearing, and may have constitutional 
symptoms such as feeling tired, continued weakness, decreased appetite, and difficulty 
returning to pre-illness weight. Additionally, they develop antibodies against Ebola that last 
at least 10 years, but it is unclear if they are immune to repeated infections. If someone 
recovers from Ebola, they can no longer transmit the disease. (CDC, 2014.) 
 
2.2   CAUSE 
EVD in humans is caused by four of five viruses of the genus Ebolavirus. The four are 
Bundibugyo virus (BDBV), Sudan virus (SUDV), Taï Forest virus (TAFV) and one simply 
called Ebola virus (EBOV, formerly Zaire Ebola virus), EBOV species, Zaire Ebola virus, is 
the most dangerous of the known EVD-causing viruses, and is responsible for the largest 
number of outbreaks. The fifth virus, Reston virus (RESTV), is not thought to cause disease 
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in humans, but has caused disease in other primates. All five viruses are closely related to 
Marburg viruses (Hoenen, 2012; Funk and Kumar, 2014). 
 
2.3   VIROLOGY 
Ebolaviruses contain single-stranded, non-infectious RNA genomes, which contain seven 
genes including 3'-UTR-NP-VP35-VP40-GP-VP30-VP24-L-5'-UTR. The genomes of the 
five different ebolaviruses (BDBV, EBOV, RESTV, SUDV and TAFV) differ in sequence, 
the number and location of gene overlaps. As with all filoviruses, ebolavirus virions are 
filamentous particles that may appear in the shape of a shepherd's crook, of a "U" or of a "6," 
and they may be coiled, toroid or branched. In general, ebolavirions are 80 nanometers (nm) 
in width and may be as long as 14,000 nm (Chipaux, 2014; Caihshort and Labiling, 1995). 
Their life cycle is thought to begin with a virion attaching to specific cell-surface receptors 
such as C-type lectins, DC-SIGN, or integrins, which is followed by fusion of the viral 
envelope with cellular membranes. The virions taken up by the cell then travel to acidic 
endosomes and lysosomes where the viral envelope glycoprotein GP is cleaved. This 
processing appears to allow the virus to bind to cellular proteins enabling it to fuse with 
internal cellular membranes and release the viral nucleocapsid. The Ebolavirus structural 
glycoprotein (known as GP1,2) is responsible for the virus' ability to bind to and infect 
targeted cells.( Chippaux, 2014). The viral RNA polymerase, encoded by the L gene, partially 
uncoats the nucleocapsid and transcribes the genes into positive-strand mRNAs, which are 
then translated into structural and nonstructural proteins. The most abundant protein produced 
is the nucleoprotein, whose concentration in the host cell determines when L switches from 
gene transcription to genome replication. Replication of the viral genome results in full-
length, positive-strand antigenomes that are, in turn, transcribed into genome copies of 
negative-strand virus progeny. Newly synthesized structural proteins and genomes self-
assemble and accumulate near the inside of the cell membrane. Virions bud off from the cell, 
gaining their envelopes from the cellular membrane from which they bud from. The mature 
progeny particles then infect other cells to repeat the cycle. The genetics of the Ebola virus 
are difficult to study because of EBOV's virulent characteristics. (Feldmann, 2005; 
Goeijenbier et al., 2014) 
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2.4   TRANSMISSION (LIFE CYCLES OF THE EBOLAVIRUS) 
 
Figure 1: Life cycles of the Ebolavirus (CDC, 2015) 
 
Between people, Ebola disease spreads only by direct contact with the blood or body fluids of 
a person who has developed symptoms of the disease. Body fluids that may contain ebola 
viruses include saliva, mucus, vomit, feces, sweat, tears, breast milk, urine and semen 
(Nishiura and Chowell, 2014). Entry points for the virus include the nose, mouth, eyes, open 
wounds, cuts and abrasions. Ebola may be spread through large droplets; however, this is 
believed to occur only when a person is very sick, that is if a person is splashed with droplets. 
Contact with surfaces or objects contaminated by the virus, particularly needles and syringes, 
may also transmit the infection. The virus is able to survive on objects for a few hours in a 
dried state, and can survive for a few days within body fluids. 
 
The Ebola virus may be able to persist for up to 8 weeks in the semen after recovery, which 
could lead to infections via sexual intercourse. Ebola may also occur in the breast milk of 
women after recovery, and it is not known when it is safe to breastfeed again, otherwise, 
people who have recovered are not infectious. The potential for widespread infections in 
countries with medical systems capable of observing correct medical isolation procedures is 
considered low and usually when someone has symptoms of the disease, they are unable to 
travel without assistance. Dead bodies remain infectious; thus, people handling human 
remains, in practices, such as, traditional burial rituals or more modern processes, such as, 
embalming are at risk; 69% of the cases of Ebola infections in Guinea during the 2014 
outbreak are believed to have been contracted via unprotected (or unsuitably protected) 
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contact with infected corpses during certain Guinean burial rituals (Althaus et al., 2014). 
Health-care workers treating people with Ebola are at greatest risk of infection as the risk 
increases when they do not have appropriate protective clothing such as masks, gowns, 
gloves and eye protection; do not wear it properly; or handle contaminated clothing 
incorrectly. There has been transmission in hospitals in some African countries that reuse 
hypodermic needles or health-care centers caring for people with the disease but do not have 
running water (Formenty et al., 2014). Human-to-human transmission of EBOV through the 
air has not been reported to occur during EVD outbreaks, and airborne transmission has only 
been demonstrated in very strict laboratory conditions, and, then, only from pigs to primates, 
but not from primates to primates has been effective (FART, 2015). 
 
2.5   2013 TO 2015 WEST AFRICAN OUTBREAK 
In March 2014, the World Health Organization (WHO) reported a major Ebola outbreak in 
Guinea, a western African nation as researchers traced the outbreak to a two-year-old child 
who died December 2013 and the disease then rapidly spread to the neighboring countries of 
Liberia and Sierra Leone. It is the largest Ebola outbreak ever documented, and the first 
recorded in the region, In a 26 September statement, the WHO said, "The Ebola epidemic 
ravaging parts of West Africa is the most severe acute public health emergency seen in 
modern times. Never before in recorded history has a biosafety level four pathogen infected 
so many people so quickly, over such a broad geographical area, for so long." As of 14 March 
2015, 24,701 suspected cases and 10,194 deaths had been reported; however, the WHO has 
said that these numbers may be underestimated (WHO and Pan-AHO, 2014; CDC, 2015) 
 
On 8 August 2014, the WHO declared the epidemic to be an international public health 
emergency and urging the world to offer aid to the affected regions, the Director-General 
said, "Countries affected to date simply do not have the capacity to manage an outbreak of 
this size and complexity on their own. I urge the international community to provide this 
support on the most urgent basis possible." By mid-August 2014, Doctors Without Borders 
reported the situation in Liberia's capital Monrovia as "catastrophic" and "deteriorating 
daily". They reported that fears of Ebola among staff members and patients had shut down 
much of the city’s health system, leaving many people without treatment for other conditions. 
By late August 2014, the disease had spread to Nigeria, and one case was reported in Senegal 
(WHO, 2014; Althaus, 2014). On 30 September 2014, the first confirmed case of Ebola in the 
United States was diagnosed, The patient died 8 days later.( Bustillo, 2014). On 29 December 
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2014 the first case was confirmed in the United Kingdom. Aside from the human cost, the 
outbreak has severely eroded the economies of the affected countries. A Financial Times 
report suggested that the economic impact of the outbreak could kill more people than the 
virus itself. As of 23 September, in the three hardest hit countries, Liberia, Sierra Leone and 
Guinea, only 893 treatment beds were available even though the then current need was 2122 
beds. On 23 October, the Malian government confirmed its first case and, in response, 
UNMEER, in cooperation with the Logistics Cluster, air-lifted 1,050 kg of personal 
protective equipment (PPE) and body bags from Monrovia to Mali.(Salaam-Blyther, 2014). 
 
2.6   2014 DRC CONGO OUTBREAK 
An outbreak in Boende District in Equatorial Province was stopped effectively with flexible 
organization and funding, as well as social mobilization led by UNICEF advising action 
people could use. The DRC recent outbreak was from a local Ebola strain and not the one 
from West Africa (WHO and Pan-AHO, 2014). 
 
3.0   DEVELOPMENT OF S-I-S COMPARTMENTAL MODEL 
                          β I    µ 
 
This is a case where a susceptible individual becoming infected is treaded, and then returns 
back to the susceptible population status as a compartment (Kamalu and Okolie, 2013) 
          (1) 
           (2) 
           (3) 
Putting   into eqn (2) 
 
 
Integrating; 
 
 
 
 ;    
S  I S 
 
I ≡ A(β - µ - βI) + BI 
If I = 0: A=  
If B - µ - ΒI = 0:  I = B  , B =  
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Then,  
or      ;   if  
Then,   
or    
 
Replacing      ;    
 
Still expanding the exponential term, we have; 
 
 
 
(4) 
Taking the first derivative of equation (4) yields equation (5) thus; 
 
 
 
                                                                              (5) 
Taking the second derivative of equation (4) or first derivative of equation (5) and equating to 
zero, yields equation (6) the peak time; 
D
2
I(t) = 0 
 
              
  
                                                                            (6) 
 
 
3.1   COLLECTIONTION OF DATA 
The data for the validation of the ebola models were obtained from credible internet sources, 
Althaus et al 2014, WHO (2014), CDC (2015) and Althaus (2014) as indicated in Tables 1a, 
1b, 1c below. 
 
  
tpk  
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Table 1a: Cases, Deaths of Ebola Fatality Epidemics In Guinea, Liberia, Sierraleone, CDC (2015), Althaus (2014) 
Months Feb-14 Mar-14 Apr-14 May-14 Jun-14 July-14 Aug-14 Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15  
Days 0 31 61 92 122 153 184 214 245 275 306 337 365  
Gunea cases 0 122 196 240 300 410 475 720 1188 1750 2250 2820 3063  
Guinea death 0 80 100 125 188 300 340 475 730 1050 1375 1750 2000  
% 0 66% 51% 52% 63% 73% 72% 66% 61% 60% 61% 61% 65%  
Liberal Cases 0 0 0 0 107 125 350 1750 4000 6625 7750 7875 8875  
Liberal deaths 0 0 0 0 65 90 125 875 2000 2750 3250 3600 3875  
% L Fatality 0 0 0 0 61% 72% 36% 50 50 42 42 46% 44%  
S.Leone  cases 0 0 0 50 150 250 500 1125 2625 5250 7750 10000 11125  
S.Leone deaths 0 0 0 6 69 100 250 400 625 1500 1750 3125 3625  
% S.L fatality 0 0 0 12% 46% 40% 50% 36% 24% 29% 23% 31% 33%  
W.A Cases 0 122 196 290 557 785 1325 3595 7813 13625 17750 20695 23063  
W.A death 0 80 100 131 322 490 715 1750 3355 5300 6375 8475 9500  
% Fatality 0 66 51 45 58 62 54 49 43 39 36% 41 41  
Gui cum. cases 0 122 318 558 858 1268 1743 2463 3651 5401 7651 10471 13534 GCC 
Gui cum. Death 0 80 180 305 493 793 1133 1608 2338 2388 4763 6513 8513 GCD 
 0 66 117 169 232 305 377 433 504 564 625 686 751 GCF 
Lib.cum. cases 0 0 0 0 107 232 582 2332 6332 12957 20707 28582 37457 LCC 
Lib.cum. deaths 0 0 0 0 65 155 280 1155 3155 5905 9155 12755 16630 LCD 
Cum.  Fatality 0 0 0 0 61 133 169 219 269 311 353 399 443 LCD 
S.L. cum Cases 0 0 0 50 200 450 950 2075 4700 99500 17700 27700 38825 SCC 
S.L.cum deaths 0 0 0 6 75 175 450 850 1450 2950 4700 7825 11450 SCD 
Cum fatality 0 0 0 12 58 98 148 184 208 237 260 2991 324 SCF 
W.A. cum. 
Cases 
0 122 318 608 1165 1950 3275 6870 14683 28308 46058 66753 89816 WCC 
W.A. cum. 
Deaths 
0 80 180 311 633 1123 1838 3588 6943 12243 18618 27093 36593 WCD 
Cum. fatality 0 66 117 162 220 282 336 385 428 467 503 544 585 WCF 
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Table 1b: Out Break Cases, Death Fatality and Previous Ebola Virus Epidemics in Central Africa, WHO (2014), Chowell et al (2004) 
Country Virus 
Species 
1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994  
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  
Congo, (Zaire 
Bundibugyo) 
 
380 
318 
1 
1 
 
 
                 
Gabon 
(Zaire) 
                   
31 
52 
 
Sudan 
(Sudan) 
 
 
151 
284 
  
22 
34 
                
Central Africa  
431 
602 
1 
1 
 
22 
34 
              
31 
52 
 
CACF 0 72 144 216 287 358 429 500 571 642 713 784 855 926 997 1068 1139 1210 1281 1352  
CACC 
CACD 
0 
0 
431 
602 
432 
603 
432 
603 
454 
637 
454 
637 
454 
637 
454 
637 
454 
637 
454 
637 
454 
637 
454 
637 
454 
637 
454 
637 
454 
637 
454 
637 
454 
637 
454 
637 
454 
637 
485 
689 
 
Country Virus 
Species 
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012    
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37    
Congo, (Zaire 
Bundibugyo) 
254 
315 
     
44 
59 
 
157 
178 
 
10 
12 
 
187 
264 
14 
32 
 
 
  
29 
57 
   
Gabon 
(Zaire) 
 
67 
92 
    
53 
65 
              
Ugander (Sudan 
Bundibugyo) 
     
224 
425 
      
37 
149 
   
1 
1 
 
21 
31 
   
Sudan 
(Sudan) 
         
7 
17 
           
Central 
Africa 
254 
315 
67 
92 
   
224 
425 
97 
124 
 
157 
178 
7 
17 
10 
12 
 
224 
413 
14 
32 
  
1 
1 
50 
88 
   
CACF 1426 1500 1574 1648 1722 1790 1859 1928 1998 2068 2138 2208 2275 2342 2409 2476 2543 2609  CACF  
 
739 
1004 
806 
1096 
806 
1096 
806 
1096 
806 
1096 
1030 
1521 
1127 
1645 
1127 
1645 
1284 
1823 
1291 
1840 
1301 
1852 
1301 
1852 
1515 
2265 
1529 
2297 
1529 
2297 
1529 
2297 
1530 
2298 
1580 
2386 
66% 
CACC 
CACD 
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Table 1c:  Cases, Death and Fatality of Ebola Epidemic In Nigeria (Althaus et al, 2014; 
Salaam-Blyther, 2014) 
20 July 27 July 3
rd
 Aug 10
th
 Aug 17
th
 Aug 24rd Aug 31
st
 Aug 7 Sept 14
th
 Sept  
 7 14 21 28 35 42 49 56  
NCC O 
No of cases 
03 12 14 16 17 18 20 20  
NCD 0 
No of deaths 
0 2 4 5 6 7 8 8  
NCF 0 17 29 31 35 39 40 40  
 
3.2   CURVE FITTING 
Cumulative data of the cases and deaths of Liberia, Guinea, Sierra Leone, Nigeria and 
Central African countries were used to produce scatter diagrams. The cumulative model 
equation (4) was superimposed on these cumulative scatter diagrams using matlab toolbox 
7.9 to ascertain the goodness of fit of the data collected, which and all, give sigmoidal 
profiles. 
 
Subsequently the first derivative of the developed model (5) were also used to plot the first 
derivative of the cumulative data produced by the computer as dumbbell profiles. In these 
way, the plots of different countries where made. 
 
4.0   RESULTS PRESENTATION 
The results of the curve-fitting done in the previous section are here presented in figs 2a to 6b 
and 7-10, and also the inherent tables 2a to 6b respectively. 
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Fig 2a: No of Guinean cumulative cases or deaths  Fig 2b: Monthly Guinean Cases or Deaths 
vs time (Cases-R2=0.9997,Deaths-R2=0.9997)  vs time 
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Fig 3a: No of Liberian cumulative cases or deaths Fig 3b: Monthly Liberian Cases or Deaths 
vs time (Cases-R2=0.9977,Deaths-R2=0.9977)  vs time 
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Fig 4a: No of S.Leone cumulative cases or deaths Fig 4b: Monthly S.Leone Cases or Deaths 
vs time (Cases-R2=0.9996,Deaths-R2=0.9995)  vs time 
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Fig 5a: No of Nigerian cumulative cases or deaths   Fig 5b: Daily Nigerian Cases or Deaths vs time 
vs time (Cases-R2=0.9566,Deaths-R2=0.9914) 
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Fig 6a: Number of Central African Cummulative         Fig 6b: Central Africa annual cases or deaths 
cases and deaths vs time                                                  or deaths vs time 
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Fig 7: Guinean cumulative cases versus  S.Leone  Fig 8: Guinean cumulative deaths versus 
and Liberian cumulative cases    S.Leone and Liberia cumulative deaths 
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Fig 9: Guinean monthly cases versus S.Leone  Fig 10: Guinean monthly deaths versus S.Leone 
and Liberia monthly cases   and Liberia monthly deaths 
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Table 2a: Coefficients and Goodness of fits for Guinean ebola cumulative cases with 95 
confidence bound 
GCC  
B =0.00483 
R0 =1.172 
U = 1.283 x 104 
a = 1.2 
u = 0.07957 
U: = F(1396)=36346.3 
tpk = F(403=)124.329 
SSE = 7.635 X 104 
R2=0.9997 
R adjusted =0.9995 
RMSE =97.69 
 
Table 2b: Coefficients and Goodness of fits for Guinean ebola cumulative deaths with 
95 confidence bound 
GCD  
B =0.0074 
R0 = 
U = 1.78 
a = 1.854 
u = 0.07543 
U: = F(1367)=24384.4 
tpk = F(412)=81.8232 
SSE = 2.23 X 104 
R=0.9997 
Adj R =0.9996 
RMSE =5385f 
 
Table 3a: Coefficients and Goodness of fits for Liberian ebola cumulative cases with 95 
confidence bound 
B =0.00748 
R0 =1.33 
U = 1.354 x 104 
a = 28.87 
u = 0.07909 
U: = F(841)=47196 
tpk = F(317)=307.947 
SSE = 4.427 
R=0.9977 
R adjusted =0.9966 
 
Table 3b: Coefficients and Goodness of fits for Liberian ebola cumulative deaths with 
95 confidence bound 
LCD  
B =0.01744 
R0 =1.043 
U = 1.502 x 10
4
 
a = 48.29 
u = 0.5819 
U: = F(774)=21462 
tpk = F(319)133.71 
SSE = 8.685 X 10
4 
R
2=
0.9977 
R
2
 Adjusted =0.9966 
RMSE =329.5
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Table 4a: Coefficients and Goodness of fits for Sierra Leonean ebola cumulative cases 
with 95 confidence bound 
SCC  
B =0.00483 
R0 =1.172 
U = 1.283 x 10
4
 
a = 1.2 
u = 0.07957 
U: = F(1396)=36346.3 
tpk = F(403=)124.329 
SSE = 7.635 X 10
4
 
R=0.9997 
R adjusted =0.9995 
RMSE =97.69
 
 
Table 4b: Coefficients and Goodness of fits for Sierra Leonean ebola cumulative deaths 
with 95 confidence bound 
SCD  
B =0.01011 
R
0 
=1.142 
U = 1.354 x 10
4
 
a = 26.63 
u = 0.1456 
U: = F(953628)=27 
tpk = F(382)=142.496 
SSE = 7.228 X 10
4
 
R=0.9995 
R adjusted=0.9993 
RMSE =95.05
 
 
Table 5a: Coefficients and Goodness of fits for Nigerian ebola cumulative cases with 95 
confidence bound 
NCC  
B =0.13 
R0 =1.778 
U = 15.28 
a = 0.5497 
u = 0.2144 
U: = F(89.3)=19.5156 
tpk = F(8.6)=0.813403 
SSE = 2.227 
R=0.9914 
R adjusted 
=0.98 
RMSE 
=0.8616 
 
Table 5b: Coefficients and Goodness of fits for Nigerian ebola cumulative deaths with 
95 confidence bound 
NCD  
B =0.3353 
R0 =1.098 
U = 18.68 
a = 2.706 
u = 1.495 
U: = F(98.4)=8.1468 
tpk = F(14.5)=0.297542 
SSE = 0.118 
R=0.9979 
R adjusted =0.9951 
RMSE =0.1983 
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Table 6a: Coefficients and Goodness of fits for Central African ebola cumulative cases 
with 95 confidence bound. 
CACC  
B =0.00731 
R0 =2.191 
U = 2739 
a = 0.4553 
u = 0.04848 
U: = F(70)=311.617 
tpk = F(281)=21631.3 
SSE = 1.116 X 10
6
 
R=0.9343 
R adjusted =0.9264 
RMSE =183.9 
 
Table 6b: Coefficients and Goodness of fits for Central African ebola cumulative deaths 
with 95 confidence bound 
CACD  
B =8.564 
R0 =1.35 
U = 1.053 x 10
6 
a = 239.5 
u = 0.1673 
U: = F(297)=105.519 
tpk = F(403=)124.329 
SSE = 5.178 X 10
5
 
R=0.9304 
R adjusted =0.9219 
RMSE =125.3
 
 
4.1   RESULT DISCUSSION 
Generally, it is seen from the plots that the cumulative number of cases or ultimate cases are 
higher than that of cumulative number or ultimate deaths as should be. Also, in the timely 
cases or deaths the peaks of the timely cases are higher than the peak of the timely death as it 
should be. In the case of Guinea, the ultimate number of cases and deaths are 36346 and 
24384. 
 
The peak of the monthly cases and deaths occur at 403 months with 124 cases and 412 
months for 82 deaths respectively, so that the peak fatality will be  or 65.8%. The 
reproductive number of cases is R0 = 1.172. 
 
The Liberia ultimate number of cases and deaths are 47196 and 21462 respectively. The 
peaks of the monthly cases and deaths occur at 317 months with 308 cases and 319 months 
with 134 deaths so that the peak percentage fatality will be  or 43.4%. The reproductive 
number of cases and deaths are 1.33 and 1.043 respectively. 
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The Sierra Leone ultimate cases is 61467, and 27628 deaths. The peaks of the monthly cases 
and deaths will be 344 months at 379 cases and 382 months at 142 deaths, so that the 
monthly fatality will be  or 37.6%. The reproductive number for the cases and deaths are 
1.172 and 1.142 respectively. 
 
In Nigeria, the ultimate cases was 20 and the number of deaths 8. The daily peak of the cases 
occur at 8.6 days as 0.8134 and that of the deaths occur at 14.5 days as 0.2975 so that the 
daily fatality will be 36.6%. 
 
For Central Africa, the ultimate cases was 21631 while the ultimate deaths stood at 12433. 
The annual peaks occurred at 70 years as 312 cases and 57 years for 106 deaths, so that the 
annual percentage fatality is  or 33.9%. The reproductive number for cases and deaths in 
Central Africa are 2.191 and 1.35 respectively. 
 
Hence, amongst the worst hot West African countries, Guinea had the highest monthly peak 
fatality 66% followed by Liberia 43%, then Sierra Leone 38%. The numerical values from 
Central Africa, the 3-worst-hit countries of West Africa and Nigeria cannot be compared 
strictly because these regions have test data on different time-frames, ie in years, months and 
days respectively. 
APPENDIX A (S-I-S ENDEMIC MODEL) 
 
 
 
 
 
    
 (A1) 
       
 (A2) 
S I S 
µ
 µ  
µ µ µ 
β I 
Birth (N) 
ɤ
 µ  
Death Death Death 
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 (A3) 
Put (A3) into (A2) 
    
Integrating; 
  
 or  
Taking antilog;     
 
  
           
 (A6) 
 
Differentiating (A4) twice or eqn (A6) once and equate to zero to yield eqn (A7) the peak time; 
 = 0 
 
 
 
         
           
 (A7) 
where   
and reproductive number  
 
 
 
 =  
 
tpk  
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5.0   CONCLUSION 
In this work, Ebola epidemic outbreak cases and deaths were modeled using compartmental 
model of epidemic mathematics and kinetics. Data were obtained from credible internet 
sources like Centers for Disease Control (CDC) and World Health Organization (WHO) 
which were used to validate our model, and the results show that it was almost a perfect 
model for some countries of West Africa but just good enough for Central Africa as the R
2
 
shows. The goodness of fit terms of coefficient of correlation (R
2
) of the developed model on 
test data gives excellent validation. For Guinea, R
2
 is 0.9997 for both cases and deaths test 
data. For Liberia, R
2
 is 0.9977 for both cases and deaths test data. For Sierra Leone, R
2
 is 
0.9997 (for cases) and 0.9995 (for deaths data). For Nigeria, R
2
 is 0.9914 (for cases data) and 
0.9979 (for deaths data). For Central Africa, R
2
 is 0.9343 (for cases data) and 0.9304 (for 
deaths data)The response plot of the cumulative cases and deaths as well as the monthly cases 
and deaths between the three worst-hit countries, namely (Liberia, Guinea. Sierra Leone) 
show very serious interaction since the EVD is spread by bats, gorillas, herbivorous animals 
that live in the bush and thick forest. We should reduce the rate of contact with the animals 
and stop eating them especially their carcasses found in the bushes and thickets. These 
findings can be used in studying future ebola epidemic and pandemic outbreaks by World 
Health Organization (WHO), Pan American Health Organization (Pan-AHO), Centers for 
Disease Control (CDC), etc. 
 
6.0   RECOMMENDATIONS 
The developed world should not treat with levity an outbreak of this magnitude until it 
becomes almost uncontrollable; like they did with the Central African case. 
And, if the world had taken serious study to stop the outbreak from Central Africa, perhaps, it 
could not have spread to West Africa and other countries as it did, since we know now that 
the world is a global village. 
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